Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on NPS Pharmaceuticals

Related NPSP
Benzinga's Top Initiations
UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on NPS Pharmaceuticals (NASDAQ: NPSP), and raised its price target from $13.00 to $15.00.

Jefferies noted, “As expected, FDA's AdComm panel voted for recommending approval of Gattex unanimously. Panel also voted favorably on NPSP's proposed REMS (10-1), supporting likely timely approval (PDUFA date, 12/30/12). With potential approval of a 2nd product Natpara in ~mid-2014, we see significant upside in NPSP shares from current levels. Reiterate Buy.”

NPS Pharmaceuticals closed on Tuesday at $10.19.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (NPSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free